Incretin Drugs for Diabetes Management

Author(s): Rania Al Nounou

The prevalence of type 2 diabetes, is increasing at an alarming rate, with only half of patients achieving the recommended HbA1c target. This study tends to focus on incretin based treatment for type 2 diabetes, and their utility in clinical practice specifically in private clinical practice in Abu Dhabi, Incretin drug group, stimulates insulin secretion and inhibit glucagon production, they also improve betacell health, slow gastric emptying, promote early satiety and reduce food intake (Nyenwe EA 2011). This study is a clinical audit supported by literature review that shows new drugs for diabetes management and despite being expensive, still do not reach the target of diabetes control. A lot of gaps in our clinical practice, especially primary care level need to be modified to achieve holistic management.